Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742).
Ma, Brigette B Y
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology 05 2018 - 1412-1418 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2017.77.0388 doi
Adult
Aged
Antineoplastic Agents, Immunological--therapeutic use
Biomarkers, Tumor--metabolism
Disease Progression
Female
HLA Antigens--metabolism
Humans
Male
Middle Aged
Nasopharyngeal Carcinoma--drug therapy
Neoplasm Recurrence, Local--drug therapy
Nivolumab--therapeutic use
Programmed Cell Death 1 Receptor--metabolism
Survival Rate
Treatment Outcome
Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology 05 2018 - 1412-1418 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
1527-7755
10.1200/JCO.2017.77.0388 doi
Adult
Aged
Antineoplastic Agents, Immunological--therapeutic use
Biomarkers, Tumor--metabolism
Disease Progression
Female
HLA Antigens--metabolism
Humans
Male
Middle Aged
Nasopharyngeal Carcinoma--drug therapy
Neoplasm Recurrence, Local--drug therapy
Nivolumab--therapeutic use
Programmed Cell Death 1 Receptor--metabolism
Survival Rate
Treatment Outcome